DE60026287D1 - Nmr-verfahren zur bestimmung des risikos zur entwicklung von diabetes type 2 - Google Patents

Nmr-verfahren zur bestimmung des risikos zur entwicklung von diabetes type 2

Info

Publication number
DE60026287D1
DE60026287D1 DE60026287T DE60026287T DE60026287D1 DE 60026287 D1 DE60026287 D1 DE 60026287D1 DE 60026287 T DE60026287 T DE 60026287T DE 60026287 T DE60026287 T DE 60026287T DE 60026287 D1 DE60026287 D1 DE 60026287D1
Authority
DE
Germany
Prior art keywords
nmr
diabetes
patient
glucose concentration
lipoprotein
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Lifetime
Application number
DE60026287T
Other languages
English (en)
Other versions
DE60026287T2 (de
Inventor
D Otvos
W Bennett
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
North Carolina State University
University of California
Liposcience Inc
Original Assignee
North Carolina State University
University of California
Liposcience Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by North Carolina State University, University of California, Liposcience Inc filed Critical North Carolina State University
Application granted granted Critical
Publication of DE60026287D1 publication Critical patent/DE60026287D1/de
Publication of DE60026287T2 publication Critical patent/DE60026287T2/de
Anticipated expiration legal-status Critical
Expired - Lifetime legal-status Critical Current

Links

Classifications

    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/66—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving blood sugars, e.g. galactose
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
    • G01N33/6893—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids related to diseases not provided for elsewhere
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/74—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving hormones or other non-cytokine intercellular protein regulatory factors such as growth factors, including receptors to hormones and growth factors
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01R—MEASURING ELECTRIC VARIABLES; MEASURING MAGNETIC VARIABLES
    • G01R33/00—Arrangements or instruments for measuring magnetic variables
    • G01R33/20—Arrangements or instruments for measuring magnetic variables involving magnetic resonance
    • G01R33/44—Arrangements or instruments for measuring magnetic variables involving magnetic resonance using nuclear magnetic resonance [NMR]
    • G01R33/46—NMR spectroscopy
    • G01R33/465—NMR spectroscopy applied to biological material, e.g. in vitro testing
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N24/00—Investigating or analyzing materials by the use of nuclear magnetic resonance, electron paramagnetic resonance or other spin effects
    • G01N24/08—Investigating or analyzing materials by the use of nuclear magnetic resonance, electron paramagnetic resonance or other spin effects by using nuclear magnetic resonance
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2405/00—Assays, e.g. immunoassays or enzyme assays, involving lipids
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00—Detection or diagnosis of diseases
    • G01N2800/04—Endocrine or metabolic disorders
    • G01N2800/042—Disorders of carbohydrate metabolism, e.g. diabetes, glucose metabolism
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00—Detection or diagnosis of diseases
    • G01N2800/32—Cardiovascular disorders
    • G01N2800/324—Coronary artery diseases, e.g. angina pectoris, myocardial infarction
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10—TECHNICAL SUBJECTS COVERED BY FORMER USPC
    • Y10T—TECHNICAL SUBJECTS COVERED BY FORMER US CLASSIFICATION
    • Y10T436/00—Chemistry: analytical and immunological testing
    • Y10T436/14—Heterocyclic carbon compound [i.e., O, S, N, Se, Te, as only ring hetero atom]
    • Y10T436/142222—Hetero-O [e.g., ascorbic acid, etc.]
    • Y10T436/143333—Saccharide [e.g., DNA, etc.]
    • Y10T436/144444—Glucose
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10—TECHNICAL SUBJECTS COVERED BY FORMER USPC
    • Y10T—TECHNICAL SUBJECTS COVERED BY FORMER US CLASSIFICATION
    • Y10T436/00—Chemistry: analytical and immunological testing
    • Y10T436/24—Nuclear magnetic resonance, electron spin resonance or other spin effects or mass spectrometry

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Molecular Biology (AREA)
  • Hematology (AREA)
  • Physics & Mathematics (AREA)
  • Biomedical Technology (AREA)
  • Chemical & Material Sciences (AREA)
  • Immunology (AREA)
  • Urology & Nephrology (AREA)
  • General Health & Medical Sciences (AREA)
  • General Physics & Mathematics (AREA)
  • Biotechnology (AREA)
  • Pathology (AREA)
  • Medicinal Chemistry (AREA)
  • Microbiology (AREA)
  • Analytical Chemistry (AREA)
  • Biochemistry (AREA)
  • Food Science & Technology (AREA)
  • Cell Biology (AREA)
  • Diabetes (AREA)
  • Spectroscopy & Molecular Physics (AREA)
  • High Energy & Nuclear Physics (AREA)
  • Condensed Matter Physics & Semiconductors (AREA)
  • Endocrinology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Investigating Or Analysing Biological Materials (AREA)
DE60026287T 1999-04-22 2000-04-19 Nmr-verfahren zur bestimmung des risikos zur entwicklung von diabetes type 2 Expired - Lifetime DE60026287T2 (de)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US13061299P 1999-04-22 1999-04-22
US130612P 1999-04-22
PCT/US2000/010463 WO2000065366A1 (en) 1999-04-22 2000-04-19 Nmr-method for determining the risk of developing type 2 diabetes

Publications (2)

Publication Number Publication Date
DE60026287D1 true DE60026287D1 (de) 2006-04-27
DE60026287T2 DE60026287T2 (de) 2006-08-17

Family

ID=22445506

Family Applications (1)

Application Number Title Priority Date Filing Date
DE60026287T Expired - Lifetime DE60026287T2 (de) 1999-04-22 2000-04-19 Nmr-verfahren zur bestimmung des risikos zur entwicklung von diabetes type 2

Country Status (9)

Country Link
US (1) US6518069B1 (de)
EP (1) EP1171778B1 (de)
JP (1) JP4585693B2 (de)
AT (1) ATE319105T1 (de)
AU (1) AU4469300A (de)
CA (1) CA2367820C (de)
DE (1) DE60026287T2 (de)
ES (1) ES2256000T3 (de)
WO (1) WO2000065366A1 (de)

Families Citing this family (50)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7395158B2 (en) * 2000-05-30 2008-07-01 Sensys Medical, Inc. Method of screening for disorders of glucose metabolism
US20040236673A1 (en) 2000-10-17 2004-11-25 Eder Jeff Scott Collaborative risk transfer system
CA2331116A1 (en) 2001-01-15 2002-07-15 Chenomx, Inc. Compound identification and quantitation in liquid mixtures -- method and process using an automated nuclear magnetic resonance measurement system
EP1384073A2 (de) * 2001-04-23 2004-01-28 Metabometrix Limited Verfahren zur analyse spektraler daten und deren anwendungen: osteoporese
US7901873B2 (en) 2001-04-23 2011-03-08 Tcp Innovations Limited Methods for the diagnosis and treatment of bone disorders
US20040142403A1 (en) * 2001-08-13 2004-07-22 Donald Hetzel Method of screening for disorders of glucose metabolism
EP1444526B1 (de) 2001-11-13 2011-09-21 The Regents of The University of California Ionenmobilitätsanalyse biologischer partikel
US6873914B2 (en) 2001-11-21 2005-03-29 Icoria, Inc. Methods and systems for analyzing complex biological systems
US6862592B1 (en) * 2001-12-21 2005-03-01 Adobe Systems Incorporated Document processing in a cross-platform environment
EP1329716A1 (de) * 2002-01-16 2003-07-23 Roche Diagnostics GmbH Verfahren zum Austesten biologischer Proben auf Vorliegen von Stoffwechselsyndrom
US7426499B2 (en) * 2004-11-08 2008-09-16 Asset Trust, Inc. Search ranking system
US20070011049A1 (en) * 2005-07-09 2007-01-11 Eder Jeffrey S Intelligent, personalized commerce chain
US7730063B2 (en) * 2002-12-10 2010-06-01 Asset Trust, Inc. Personalized medicine service
US20080027769A1 (en) * 2002-09-09 2008-01-31 Jeff Scott Eder Knowledge based performance management system
WO2004040407A2 (en) * 2002-10-25 2004-05-13 Liposcience, Inc. Methods, systems and computer programs for deconvolving the spectral contribution of chemical constituents with overlapping signals
DE10315877B4 (de) * 2003-04-08 2005-11-17 Roche Diagnostics Gmbh Krankheitsverlaufkontrolle
US8460243B2 (en) * 2003-06-10 2013-06-11 Abbott Diabetes Care Inc. Glucose measuring module and insulin pump combination
US7722536B2 (en) * 2003-07-15 2010-05-25 Abbott Diabetes Care Inc. Glucose measuring device integrated into a holster for a personal area network device
US7197427B2 (en) * 2004-03-31 2007-03-27 Genworth Financial Inc. Method for risk based testing
CA2561536C (en) * 2004-04-01 2017-09-19 Liposcience, Inc. Nmr clinical analyzers and related methods, systems, modules and computer program products for clinical evaluation of biosamples
US7422224B2 (en) * 2004-04-13 2008-09-09 Kimir Seatpost Adjustable bicycle seat post assembly
US20060010098A1 (en) 2004-06-04 2006-01-12 Goodnow Timothy T Diabetes care host-client architecture and data management system
US7951078B2 (en) * 2005-02-03 2011-05-31 Maren Theresa Scheuner Method and apparatus for determining familial risk of disease
ATE412364T1 (de) 2005-03-15 2008-11-15 Hoffmann La Roche Verfahren und system zur untersuchung des glucosestoffwechsels
ES2525345T3 (es) * 2006-03-24 2014-12-22 Metanomics Gmbh Procedimiento de diagnóstico de diabetes de tipo II
US8498915B2 (en) * 2006-04-02 2013-07-30 Asset Reliance, Inc. Data processing framework for financial services
US8247235B2 (en) 2007-06-08 2012-08-21 Quest Diagnostics Investments Incorporated Lipoprotein analysis by differential charged-particle mobility
TW200936156A (en) 2008-01-28 2009-09-01 Novartis Ag Methods and compositions using Klotho-FGF fusion polypeptides
US8420088B2 (en) 2008-01-28 2013-04-16 Novartis Ag Methods and compositions using FGF23 fusion polypeptides
US9354200B1 (en) 2008-08-07 2016-05-31 Quest Diagnostics Investments Incorporated Detection apparatus for differential-charged particle mobility analyzer
US8386187B2 (en) * 2008-10-20 2013-02-26 Liposcience, Inc. Lipoprotein insulin resistance indexes and related methods, systems and computer programs for generating same
DE102009026651A1 (de) 2009-06-02 2011-02-17 Großmann, Kay, Dr. rer. nat. (Chemie) Verfahren und Messvorrichtung zur qualitativen und quantitativen Analyse von Körperflüssigkeiten
US9250211B2 (en) 2010-12-30 2016-02-02 Quest Diagnostics Investments Incorporated Magnetic separation of lipoproteins using dextran sulfate
US10136845B2 (en) 2011-02-28 2018-11-27 Abbott Diabetes Care Inc. Devices, systems, and methods associated with analyte monitoring devices and devices incorporating the same
WO2012163361A1 (en) * 2011-05-31 2012-12-06 Aarhus Universitet Method and system for identification of physiological imbalance in an animal
EP3686620A1 (de) 2011-06-30 2020-07-29 Liposcience, Inc. Quantitative klinische nmr-analysatoren mit automatischer nmr-temperaturempfindlichkeitskompensation zur anpassung hoher betriebsumgebungstemperaturbereiche
WO2013027191A1 (en) 2011-08-25 2013-02-28 Novartis Ag Methods and compositions using fgf23 fusion polypeptides
US9928345B2 (en) 2012-06-08 2018-03-27 Liposciences, Inc. Multiple-marker risk parameters predictive of conversion to diabetes
US9470771B2 (en) 2012-06-08 2016-10-18 Liposcience, Inc. NMR measurements of NMR biomarker GlycA
US9361429B2 (en) * 2012-06-08 2016-06-07 Liposcience, Inc. Multi-parameter diabetes risk evaluations
US20150260631A1 (en) * 2014-03-17 2015-09-17 Health Diagnostic Laboratory, Inc. System and method for assessing quanitites or sizes of lipoprotein particles from lipoprotein particle compositions
US9551768B2 (en) 2013-03-15 2017-01-24 East Carolina University NMR method for monitoring changes in the core of lipoprotein particles in metabolism and disease
DE102014203721B4 (de) * 2014-02-28 2018-12-27 Bruker Biospin Gmbh Verfahren zur Bestimmung der Konzentration einer Substanz in einer Probe
EP3210029A1 (de) 2014-10-21 2017-08-30 True Health IP LLC Detektion von quantitativer molarer konzentration von spezifischen apolipoproteinhaltigen partikeln in körperflüssigkeiten mittels kapillarelektrophorese
US20160109471A1 (en) 2014-10-21 2016-04-21 Health Diagnostic Laboratory, Inc. Lipoprotein particle number from measurements of lipoprotein particle phospholipid concentration in lipoprotein particle membrane bilayer
WO2016069639A1 (en) 2014-10-27 2016-05-06 True Health Diagnostics, Llc Lp(a) subform size identification by capillary isoteachophoresis electrophoresis with laser-induced-fluorescence
WO2016088059A1 (en) 2014-12-04 2016-06-09 Novartis Ag Methods and compositions using klotho variant polypeptides
US11156621B2 (en) * 2017-09-07 2021-10-26 Liposcience, Inc. Multi-parameter metabolic vulnerability index evaluations
US10775458B2 (en) 2018-03-05 2020-09-15 Texas Tech University System Method and system for non-invasive measurement of metabolic health
WO2023239869A1 (en) * 2022-06-09 2023-12-14 Quest Diagnostics Investments Llc Quantification of lipoprotein subfractions by ion mobility

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5869534A (en) * 1992-05-21 1999-02-09 The Picower Institute For Medical Research Glycosylation of lipids and lipid-containing particles, and diagnostic and therapeutic methods and materials derived therefrom
US4933844A (en) * 1988-09-26 1990-06-12 Otvos James D Measurement of blood lipoprotein constituents by analysis of data acquired from an NMR spectrometer
CA2071638A1 (en) 1989-12-21 1991-06-22 Eric T. Fossel Method for predicting atherosclerotic risk
WO1993003450A1 (en) 1991-07-30 1993-02-18 North Carolina State University Method and apparatus for measuring blood lipoprotein levels by nmr spectroscopy
US5585235A (en) * 1993-04-13 1996-12-17 Diagnescent Technologies, Inc. Fluorescent assay and method that corrects for spectral interference
EP0728019A4 (de) * 1993-11-08 1999-07-07 Peptide Delivery Systems Pty L Maskierte diagnostikpräparate und verfahren für ihre verwendung
US5685300A (en) 1994-04-01 1997-11-11 Kuenstner; J. Todd Noninvasive and in-vitro measurement of glucose and cholesterol by nuclear magnetic resonance spectroscopy
US6163154A (en) 1997-12-23 2000-12-19 Magnetic Diagnostics, Inc. Small scale NMR spectroscopic apparatus and method
US6226082B1 (en) 1998-06-25 2001-05-01 Amira Medical Method and apparatus for the quantitative analysis of a liquid sample with surface enhanced spectroscopy

Also Published As

Publication number Publication date
WO2000065366A8 (en) 2001-03-29
WO2000065366A1 (en) 2000-11-02
US6518069B1 (en) 2003-02-11
EP1171778A1 (de) 2002-01-16
ATE319105T1 (de) 2006-03-15
AU4469300A (en) 2000-11-10
JP2002543392A (ja) 2002-12-17
DE60026287T2 (de) 2006-08-17
JP4585693B2 (ja) 2010-11-24
CA2367820A1 (en) 2000-11-02
EP1171778B1 (de) 2006-03-01
ES2256000T3 (es) 2006-07-16
CA2367820C (en) 2009-12-22

Similar Documents

Publication Publication Date Title
ATE319105T1 (de) Nmr-verfahren zur bestimmung des risikos zur entwicklung von diabetes type 2
Rice et al. CortiWatch: Watch-based cortisol tracker
CN102667485B (zh) 抑郁症的生物标记物、抑郁症的生物标记物的测定方法、计算机程序及记录介质
JPH06508440A (ja) 血糖測定用近赤外線装置の一般較正を行う方法
Dhawan et al. Asian Indians, coronary artery disease, and physical exercise
Nederveen et al. Variability in skeletal muscle fibre characteristics during repeated muscle biopsy sampling in human vastus lateralis
Price Point-of-care testing in diabetes mellitus
US20080269616A1 (en) Mir spectroscopy of tissue
CN108072618A (zh) 一种心梗后死亡风险的预测系统
US6424859B2 (en) Diagnosis of rheumatoid arthritis in vivo using a novel spectroscopic approach
ATE314648T1 (de) Diagnostisches verfahren für asthma
Schulman et al. Use of the Accusport semi-automated analyser to determine blood lactate as an aid in the clinical assessment of horses with colic
Meites et al. Studies on the quality of specimens obtained by skin puncture of children 1. Tendency to hemolysis, and hemoglobin and tissue fluid as contaminants.
Brunetti et al. Serum cotinine and silent myocardial infarction in individuals free from cardiovascular disease
Ross et al. Short-term evaluation of an electro-chemical system (ExacTech™) for blood glucose monitoring
Elliott et al. Comparison of glycated hemoglobin results based on at-home and in-lab dried blood spot sampling to routine venous blood sampling in-lab in adult patients with type 1 or type 2 diabetes
Holstein et al. Practicality and accuracy of prehospital rapid venous blood glucose determination
CA3016500C (en) Direct infrared analysis of post-translational modification of proteins
Krøll et al. On the use of patient data for the definition of reference intervals in clinical chemistry
Joy et al. Glycemic Control and Clinico-Electrophysiological Severity of Diabetic Polyneuropathy
Rouholiman et al. Rapid Lifestyle Prototyping: Assessment of Infrared Spectroscopic Blood Responses for Short-term Lifestyle Interventions
Ureta Non-invasive Glucose Test as an Alternative Detector for Diabetes Mellitus: Basis for the Development of Laboratory Activity for Grade 10 Science
Voss et al. Determining acceptability of blood glucose meters: design of meter evaluations
Tonstad et al. Action levels for obesity treatment in 40 to 42-y-old men and women compared with action levels for prevention of coronary heart disease
EP3426153A1 (de) Direkte infrarotanalyse der posttranslationalen modifikation von proteinen

Legal Events

Date Code Title Description
8364 No opposition during term of opposition